CYCN (Cyclerion Therapeutics, Inc. Common Stock) Stock Analysis - AI Report
Cyclerion Therapeutics, Inc. Common Stock (CYCN) is a publicly traded Healthcare sector company. As of May 21, 2026, CYCN trades at $3.02 with a market cap of $13.08M and a P/E ratio of -2.27. CYCN moved +4.33% today. Year to date, CYCN is +123.19%; over the trailing twelve months it is -6.21%. Its 52-week range spans $1.03 to $9.47. Rallies surfaces CYCN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What is the AI research view on CYCN?
Rallies AI research for CYCN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
Slate Path Capital LP sold 357.88K (~$555.11K) on Nov 21, 2024.
MCGUIRE TERRANCE sold 8 (~$27.16) on Aug 9, 2023.
MCGUIRE TERRANCE bought 92.83K (~$289.63K) on Jun 3, 2021.
CYCN Analyst Consensus
CYCN analyst coverage data. Average price target: $0.00.
Common questions about CYCN
What is the AI research view on CYCN?
Rallies AI research for CYCN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for CYCN?
Rallies AI research for CYCN combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is CYCN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CYCN. It does not provide personalized investment advice.
